- Home
- NET vs REGN Comparison
NET vs REGN Comparison
Compare NET & REGN Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- NET
- REGN
- Stock Information
- Founded
- NET 2009
- REGN 1988
- Country
- NET United States
- REGN United States
- Employees
- NET N/A
- REGN N/A
- Industry
- NET Computer Software: Prepackaged Software
- REGN Biotechnology: Pharmaceutical Preparations
- Sector
- NET Technology
- REGN Health Care
- Exchange
- NET Nasdaq
- REGN Nasdaq
- Market Cap
- NET 74.4B
- REGN 59.5B
- IPO Year
- NET 2019
- REGN 1991
- Fundamental
- Price
- NET $219.31
- REGN $575.06
- Analyst Decision
- NET Buy
- REGN Buy
- Analyst Count
- NET 26
- REGN 23
- Target Price
- NET $192.35
- REGN $794.83
- AVG Volume (30 Days)
- NET 2.0M
- REGN 947.1K
- Earning Date
- NET 11-06-2025
- REGN 10-30-2025
- Dividend Yield
- NET N/A
- REGN 0.61%
- EPS Growth
- NET N/A
- REGN 5.03
- EPS
- NET N/A
- REGN 39.67
- Revenue
- NET $1,881,431,000.00
- REGN $14,214,200,000.00
- Revenue This Year
- NET $28.05
- REGN N/A
- Revenue Next Year
- NET $26.43
- REGN $4.86
- P/E Ratio
- NET N/A
- REGN $14.50
- Revenue Growth
- NET 27.32
- REGN 5.38
- 52 Week Low
- NET $77.60
- REGN $476.49
- 52 Week High
- NET $230.10
- REGN $1,165.85
- Technical
- Relative Strength Index (RSI)
- NET 59.49
- REGN 53.36
- Support Level
- NET $220.43
- REGN $558.54
- Resistance Level
- NET $229.54
- REGN $570.76
- Average True Range (ATR)
- NET 7.01
- REGN 13.98
- MACD
- NET 1.09
- REGN -1.01
- Stochastic Oscillator
- NET 64.86
- REGN 50.33
About NET Cloudflare Inc.
Cloudflare is a software company based in San Francisco, California, that offers security and web performance offerings by utilizing a distributed, serverless content delivery network, or CDN. The firm's edge computing platform, Workers, leverages this network by providing clients the ability to deploy, and execute code without maintaining servers.
About REGN Regeneron Pharmaceuticals Inc.
Regeneron Pharmaceuticals discovers, develops, and commercializes products that fight eye disease, cardiovascular disease, cancer, and inflammation. The company has several marketed products, including low-dose Eylea and Eylea HD, approved for wet age-related macular degeneration and other eye diseases; Dupixent in immunology; Praluent for LDL cholesterol lowering; Libtayo in oncology; and Kevzara in rheumatoid arthritis. Regeneron is also developing monoclonal and bispecific antibodies with Sanofi, other collaborators, and independently, and has earlier-stage partnerships that bring new technology to the pipeline, including RNAi (Alnylam) and Crispr-based gene editing (Intellia).